Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

NCT06976944 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Triple-Negative Breast Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Paclitaxel
DRUG: Bevacizumab

Sponsor

Yukinori Ozaki

Collaborators

[object Object]